IP And Trademarks 14 November 2026
New HIV Drug Faces 18 Patent Filings, Generics Delayed
An innovative HIV treatment has attracted 18 patent applications in India, with potential grants extending protection until 2042, 28 years after the initial filing. Experts warn that these patents could postpone the entry of affordable generic versions, impacting patients seeking cost‑effective therapy.
Key points
- 18 new patent filings filed for a breakthrough HIV drug in India.
- If granted, patents would run until 2042, 28 years after the first filing.
- The extended protection may push back the launch of cheaper generic versions, limiting access for patients.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.
